> top > docs > PMC:7386875 > spans > 50660-52164 > annotations

PMC:7386875 / 50660-52164 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T507 323-331 Body_part denotes platelet http://purl.org/sig/ont/fma/fma62851
T508 538-547 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T509 753-761 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T510 987-997 Body_part denotes neutrophil http://purl.org/sig/ont/fma/fma62860
T511 1244-1252 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T378 94-102 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T379 300-308 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T380 636-644 Disease denotes thrombus http://purl.obolibrary.org/obo/MONDO_0000831
T381 675-685 Disease denotes thrombosis http://purl.obolibrary.org/obo/MONDO_0000831
T382 1311-1332 Disease denotes hereditary angioedema http://purl.obolibrary.org/obo/MONDO_0019623
T383 1322-1332 Disease denotes angioedema http://purl.obolibrary.org/obo/MONDO_0010481

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T532 158-168 http://purl.obolibrary.org/obo/CLO_0001658 denotes Activation
T533 213-223 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T534 399-409 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T535 492-502 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T536 658-664 http://purl.obolibrary.org/obo/NCBITaxon_33208 denotes animal
T537 765-771 http://purl.obolibrary.org/obo/NCBITaxon_33208 denotes animal
T538 829-830 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T539 921-922 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T540 975-985 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T541 1225-1226 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T542 1253-1256 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T543 1358-1359 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T84764 246-255 Chemical denotes molecules http://purl.obolibrary.org/obo/CHEBI_25367
T40796 413-423 Chemical denotes bradykinin http://purl.obolibrary.org/obo/CHEBI_3165
T14978 1017-1019 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T87766 1072-1082 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T87872 1410-1433 Chemical denotes anti-inflammatory drugs http://purl.obolibrary.org/obo/CHEBI_35472
T434 1428-1433 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T73 1322-1332 Phenotype denotes angioedema http://purl.obolibrary.org/obo/HP_0100665

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T155 481-502 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation
T156 645-654 http://purl.obolibrary.org/obo/GO_0009058 denotes formation
T157 703-713 http://purl.obolibrary.org/obo/GO_0007599 denotes hemostasis
T158 791-812 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammatory response
T159 964-985 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation
T160 987-1011 http://purl.obolibrary.org/obo/GO_0043312 denotes neutrophil degranulation

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T173 0-157 Sentence denotes The inhibition of FXII as means to inhibit the thromboinflammatory response incited by severe COVID-19 appears an attractive and rational therapeutic target.
T174 158-1471 Sentence denotes Activation of the contact pathway is initiated by FXII activation by negatively charged molecules such as NETs, which are increased in severe COVID-19 patients, and platelet-derived PolyP.100 This leads to the generation of thrombin and the activation of bradykinin, of which the latter in particular results in downstream complement activation and the production of inflammatory cytokines.149 Importantly, therapeutic inhibition of FXIIa demonstrates protection from occlusive thrombus formation in animal models of thrombosis without impeding hemostasis.150 Treatment with an inhibitory FXIIa antibody in animal models of systemic inflammatory response syndrome, using a lethal E coli challenge, have shown that FXIIa inhibition improves survival and decreases a number of inflammatory markers including complement activation, neutrophil degranulation, and IL-6.151–153 Importantly, the potential safety of FXII inhibitors is highlighted by the fact that FXII-deficient individuals display no bleeding phenotype, and there is no known effect on immune function.154 A FXIIa inhibitory antibody has recently entered clinical trials for the treatment of hereditary angioedema and therefore represents a promising novel combination of antithrombotic and anti-inflammatory drugs (URL: https://www.clinicaltrials.gov.
T175 1472-1504 Sentence denotes Unique identifier: NCT03712228).

2_test

Id Subject Object Predicate Lexical cue
32586214-29483100-21597821 346-349 29483100 denotes 100
32586214-31507606-21597822 548-551 31507606 denotes 149
32586214-7678610-21597823 1022-1025 7678610 denotes 151
32586214-32542210-21597823 1022-1025 32542210 denotes 151
32586214-8630396-21597823 1022-1025 8630396 denotes 151
32586214-22993391-21597824 1221-1224 22993391 denotes 154

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
1692 382-390 Gene denotes thrombin Gene:2147
1693 413-423 Gene denotes bradykinin Gene:3827
1694 1017-1021 Gene denotes IL-6 Gene:3569
1695 309-317 Species denotes patients Tax:9606
1696 94-102 Disease denotes COVID-19 MESH:C000657245
1697 300-308 Disease denotes COVID-19 MESH:C000657245
1698 626-644 Disease denotes occlusive thrombus MESH:D013927
1699 675-685 Disease denotes thrombosis MESH:D013927
1700 1153-1161 Disease denotes bleeding MESH:D006470
1701 1311-1332 Disease denotes hereditary angioedema MESH:D054179